Prevalence and Incidence of Metabolic Syndrome in a Cohort of Patients with Rheumatoid Arthritis: A Correlation between Body Mass Index and Disease Activity

Susana Ferreira Krampe, Nicole Pamplona Bueno de Andrade, Letícia Guimarães da Silveira, Claiton Viegas Brenol

Department of Rheumatology, Hospital de Clínicas de Porto Alegre (HCPA)-UFRGS, Porto Alegre, Brazil
Email: susanafkrampe@gmail.com

Abstract

Rheumatoid Arthritis (RA) is an inflammatory disease associated with high morbidity and increased cardiovascular disease, and Metabolic Syndrome (MS) is understood as a set of metabolic disorders that correlates with obesity and sedentary lifestyle. The aim of this study is to evaluate the prevalence of MS in a cohort of patients with RA and its correlation to specific factors of the disease. A retrospective cohort study was conducted with 283 patients with RA, followed at the Rheumatology Outpatient Clinic of the Hospital de Clínicas de Porto Alegre (HCPA) between 2008 and 2016; 187 continued to be followed and agreed to be reevaluated between January and November 2016. MS was defined according to the National Cholesterol Education Program and disease activity was assessed using the Disease Activity Score (DAS28). Clinical, biochemical, and anthropometric evaluations were conducted. The prevalence of MS in the first evaluation was 43.9% and, after 8 years, 59.4%. Increased waist circumference and blood pressures, elevated triglycerides and low High-Density Lipoprotein were the most frequent features of MS. The DAS28 was significantly lower in the reevaluation ($p = 0.006$). The prevalence of MS was higher at the end of 8 years; disease activity, as well as blood pressure, decreased during this period. Steroid use had also decreased at the end of follow-up. There was an increase of 15% of cases with MS in an 8-year follow-up cohort of patients, which was in agreement with the current literature and showed how the inflammatory process in RA is correlated to MS. The parameters of MS that varied the most were blood pressure, cholesterol and triglycerides. Ultimately, these parameters and disease activity must be observed closely in order to improve the prognosis of patients with RA.
1. Introduction

Rheumatoid Arthritis (RA) is a systemic inflammatory disease that may cause destruction and deformity of the joints and lead to a functional disability whenever it’s not properly treated. Patients with RA, especially those with an active disease, have shown a tendency to present abnormal lipid profile with low levels of high-density lipoprotein cholesterol (HDL) and high levels of triglycerides, as well as less insulin sensitivity. These clinical and laboratory findings, along with central obesity and increased blood pressure, embrace the concept of metabolic syndrome (MS), which accelerates the process of atherosclerosis and inflammation in RA patients, duplicating the risk of fatal and non-fatal cardiovascular events [1] [2] [3] [4].

Accordingly, RA and MS are considered diseases with common characteristics that may increase the risk of cardiovascular disease. Higher rates of insulin resistance and MS have been reported in patients with RA, with the rate of MS found in RA patients ranging from 14% to 56%. This wide variation can be explained by the disparity among the multiple definitions of MS, as well as differences in ethnicity, geographical area, study design and population studied [5].

The aim of the treatment for RA is remission. Moreover, the pillar treatment of synthetic or biological disease-modifying antirheumatic drugs (DMARDs) is the main responsible for reducing or reversing signs and symptoms that interfere with quality of life, disability and progression of joint damage [6]. Appropriate management may enable lower rates of disease activity, resulting in increased functional capacity and better quality of life. Early diagnosis and treatment of RA can also decrease the risk factors for MS, improving quality of life and life expectancy [6].

The aim of this study was to evaluate the components of MS in patients with RA during a long-term follow-up, as well as to correlate the variation with clinical and laboratory parameters of the disease.

2. Methods

2.1. Patients and Study Design

A retrospective cohort of 283 RA patients previously described in Cunha et al. [7] was followed at the Rheumatology Outpatient Clinic of the Hospital de Clínicas de Porto Alegre (HCPA) between 2008 and 2016. All of them fulfilled the criteria of the American College of Rheumatology (ACR) for AR and were aged at least 18 years. Patients with another connective tissue disease (except for secondary Sjögren’s syndrome) were excluded. Among them, 187 subjects were
reevaluated between January and November 2016.

MS was defined according to the National Cholesterol Education Program’s Adult Treatment Panel (NCEP-ATP III) criteria [8].

Disease activity was assessed using the Disease Activity Score (DAS-28). In addition, clinical, biochemical and anthropometric evaluations were applied. In order to avoid evaluation bias in subjective variables, such as DAS-28 and measurements of the hip and abdomen circumferences, the same researcher examined the patients during follow-up. The diagnostic criteria was the same as those assessed by Cunha [7], according to the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria [6].

The study was submitted and evaluated by the Research and Graduation Group (GPPG) and by the Internal Review Board of the HCPA, meeting their norms and guidelines. Since it was a new research with different researchers, all the participants signed a new informed consent form contemplating the current regulations.

2.2. Assessment

The patients were scheduled for evaluation, by two different trained researchers at both times, and following the protocol established: clinical, anthropometric, biochemical evaluation; blood pressure measurement; assessment of disease activity.

**Clinical evaluation:** A questionnaire designed by the authors of Cunha et al. [7] was completed about age, time since diagnosis, current medications and previous diagnosis of cardiovascular disease (CVD)—angina, acute myocardial infarction and stroke. Blood pressure (BP) was registered as the mean of two consecutive measurements, before and after the interview. It is available at the Supplementary Appendix.

**Anthropometric evaluation:** Weight was registered in kilograms (kg) and height in meters (m). The measurements were carried out as recommended by the World Health Organization [9]. Weight and height were used to calculate the Body Mass Index (BMI) = Weight/Height², classified according to the WHO [10]. Waist Circumference (WC) was measured between the anterior superior iliac spine and the last rib. The measuring instrument used was in centimeters presenting variation of the scale in millimeters (mm) [11].

**Laboratory Tests:** Total Cholesterol, HDL-c, Triglycerides, Fasting Glucose, Fasting Insulin and ultrasensitive C-Reactive Protein (CRP) were tested in the clinical laboratory of the HCPA. LDL-c was obtained by the Friedewald formula: LDL-c = (TC − HDL-c − TG/5); when serum TG < 400 mg/dl [10]. Insulin resistance (IR) was assessed by calculating the HOMA index = fasting glucose × 0.0555 × fasting insulin/22.59 and the result was considered positive when >2.114 [12], only when TG > 400 mg/dl.

**RA Activity:** According to the Disease Activity Score-28 (DAS-28), an instrument dedicated to evaluating disease activity, activity is considered high when the result is >5.1; moderate between 3.2 and 5.1; low ≤ 3.2, and remission when
≤ 2.6 [13]. DAS-28 was calculated using erythrocyte sedimentation rate (ESR) and four variables (tender joints, swollen joints, ESR and visual analog scale or VAS).

**Diagnosis of MS**: The NCEP ATPIII criteria were adopted. It required the presence of three or more of the following conditions: waist circumference > 102 cm in men or >88 cm in women, high density lipoprotein cholesterol (HDL-C) < 50 mg/dL in women and <40 mg/dL in men or on drug treatment, triglycerides 150 mg/dL or on drug treatment, blood pressure (BP) 130/85 mmHg or on anti-hypertensive treatment, and fasting glucose 100 mg/dL or on anti-diabetic drug treatment.

**Medications**: The use of Disease-Modifying Anti-Rheumatic Drugs (DMARDs) was evaluated retrospectively by the patients’ medical records and direct interviews.

### 2.3. Potential Bias

In order to avoid evaluation bias for the variables of higher subjectivity, such as DAS-28 and measurements of the hip and abdomen circumferences, the same investigator assessed the patient in 2008 and 2016.

### 2.4. Statistical Analysis

Data were analyzed using the Statistical Package for Social Sciences (SPSS) version 21.0. P ≤ 0.05 was considered significant.

The normality of the quantitative variables was verified using the Kolmogorov-Smirnov test, for the definition of parametric or non-parametric results. The deltas of the studied variables were constructed using the difference between the two evaluations.

Qualitative variables were determined by absolute and relative frequency, while quantitative variables were determined by the mean and standard deviation or interquartile range and median.

In order to compare the time-points (1st and 2nd evaluations) of the variables, the Student’s t-test was used for paired samples. In case of asymmetry, the Wilcoxon test was applied. For categorical variables, the McNemar test was used.

So as to compare means among the four groups of Metabolic Syndrome, the One-way Analysis of Variance (ANOVA) in conjunction with the Tukey’s range test was applied. In case of asymmetry, the Kruskal-Wallis and Dunn tests were used, respectively. For the comparison of categorical variables, Pearson’s chi-square test was applied.

Pearson’s correlation was carried out in order to verify the degree of correlation among the variables.

For the correction of confounding factors (age at 1st evaluation, gender, BMI variation, CRP at 1st evaluation, DAS-28 at 1st evaluation, HAQ at 1st evaluation, use of prednisone at 1st evaluation and dose of prednisone at 1st evaluation), multivariate Poisson Regression analysis was used. A p value < 0.20 in the biva-
ivariate analysis met the criteria to enter the variable in the multivariate model.

For this study, no sample size calculation was performed because the same patients from the cohort studied by Cunha et al. [7] were reevaluated, verifying the same data and current laboratory tests.

3. Compliance with Ethical Standards

3.1. Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

This study was approved to the local Ethics Committee of Hospital de Clínicas de Porto Alegre number 2014-0602.

3.2. Informed Consent

Informed consent was obtained from all participants included in the study.

4. Results

Among the 187 patients evaluated, 29 (15.5%) were men and 158 (84.5%), women. The mean age at onset was 53.5 years; the sample was mostly of Caucasians (85%); and they mostly presented a low level of education (complete or incomplete Elementary School: 72%). The sample characteristics are described in Table 1.

When we evaluated the risk factors for MS (Table 2), we noted a statistically significant reduction in disease activity according to DAS-28 (3.87 ± 1.43 vs. 3.52 ± 1.36, p = 0.006), HDL levels (58.7 ± 16.1 mg/dL vs. 55.22 ± 15.7, p < 0.001) and blood pressure (Systolic Blood Pressure: 139.1 ± 23.5 mmHg vs. 130.6 ± 24.9, p < 0.001; Diastolic Blood Pressure: 85.9 ± 12.6 mmHg vs. 82.5 ± 12.0, p < 0.001). There was, however, a significant increase in glucose levels (93.9 mg/dL ± 20.9 vs. 97.7 ± 29.1, p = 0.042) and in the prevalence of metabolic syndrome (MS) (43.9% vs. 59.4%, p < 0.001).

When the medication-related aspects were evaluated (Table 3), a statistically significant reduction was noted in the use and dosage of prednisone (55.6% vs. 39%, p < 0.001) and in the use of chloroquine diphosphate (17.6% vs. 3.7%, p < 0.001). Significant increase in the use of leflunomide (23% vs. 40.6%, p < 0.001) and biologicals (2.7% vs. 18.2%, p < 0.001) was also noted.

After follow-up, only nine patients (4.8%) no longer had metabolic syndrome. However, 38 (20.3%) did not present MS in the 1st evaluation and presented it in the second evaluation. The remaining patients (approximately 75%) had no changes in their clinical condition at follow-up, either remaining with no MS (35.8%) or persisting with MS (39%).

When the variables were associated with changes in MS (Table 4), a significant association with age was noted (p = 0.008). Younger patients had no MS at
Table 1. Demographic data.

| Variables                        | N = 187 |
|----------------------------------|---------|
| Age at 1st evaluation (years)-mean ± SD | 53.9 ± 11.0 |
| Age at 2nd evaluation (years)-mean ± SD | 61.4 ± 10.9 |
| Gender-n (%)                     |         |
| Male                             | 29 (15.5) |
| Female                           | 158 (84.5) |
| Ethnicity-n (%)                  |         |
| White                            | 159 (85.0) |
| Black                            | 20 (10.7) |
| Mixed                            | 6 (3.2) |
| Education-n (%)                  |         |
| Illiterate                       | 2 (1.1) |
| Incomplete Elementary School     | 94 (50.3) |
| Complete Elementary School       | 41 (21.9) |
| Incomplete High School           | 11 (5.9) |
| Complete High School             | 21 (11.2) |
| Incomplete University Degree     | 1 (0.5) |
| Complete University Degree       | 5 (2.7) |
| Post-graduation                  | 12 (6.4) |
| Age at diagnosis (years)-mean ± SD | 53.5 ± 11.4 |

Table 2. Comparison of RA patients regarding distribution of components, disease activity, and prevalence of MS through time.

| Variables                        | 1st evaluation (n = 187) | 2nd evaluation (n = 187) | P  |
|----------------------------------|--------------------------|--------------------------|----|
| HDL (mg/dL)                      | 58.7 ± 16.1              | 55.2 ± 15.7              | <0.001 |
| Triglycerides (mg/dL)            | 127.7 ± 57.0             | 134.8 ± 59.8             | 0.067 |
| Glucose (mg/dL)                  | 93.9 ± 20.9              | 97.7 ± 29.1              | 0.042 |
| BMI (kg/m²)                      | 26.9 ± 5.1               | 27.3 ± 5.2               | 0.069 |
| Waist circumference (cm)         | 92.9 ± 13.1              | 92.3 ± 14.1              | 0.252 |
| Systolic Blood Pressure (mmHg)   | 139.1 ± 23.5             | 130.6 ± 24.9             | <0.001 |
| Diastolic Blood Pressure (mmHg)  | 85.9 ± 12.6              | 82.5 ± 12.0              | <0.001 |
| CRP (mg/dL)                      | 5.5 (0.16 - 161)         | 5.4 (0.75 - 73.9)        | 0.069 |
| DAS-28                           | 3.87 ± 1.43              | 3.52 ± 1.36              | 0.006 |
| Moderate/high disease activity (>3.2) | 126 (67.4)             | 101 (54.0)               | 0.006 |
| HAQ                              | 1.1 (0.5 - 1.6)          | 1.1 (0.4 - 1.6)          | 0.990 |
| MS (%)                           | 82 (43.9)                | 111 (59.4)               | <0.001 |

Mean ± SD, except for minimum-maximum or IQR in CRP and HAQ, respectively.
Table 3. Drug use during follow-up.

| Variables                        | 1st evaluation (n = 187) | 2nd evaluation (n = 187) | P     |
|----------------------------------|--------------------------|--------------------------|-------|
| Use of Prednisone                | 104 (55.6)               | 73 (39.0)                | <0.001|
| Dosage of Prednisone (mg)        | 5 (0 - 10)               | 0 (0 - 5)                | <0.001|
| Methotrexate                     | 152 (81.3)               | 140 (74.9)               | 0.096 |
| Dosage of Methotrexate (mg)      | 15 (10 - 20)             | 15 (10 - 20)             | 0.002 |
| Hydroxychloroquine               | 18 (9.6)                 | 10 (5.3)                 | 0.096 |
| Hydroxychloroquine diphosphate   | 33 (17.6)                | 7 (3.7)                  | <0.001|
| Sulphasalazine                   | 16 (8.6)                 | 11 (5.9)                 | 0.424 |
| Leflunomide                      | 43 (23.0)                | 76 (40.6)                | <0.001|
| Biologicals                      | 5 (2.7)                  | 34 (18.2)                | <0.001|
| Use of Prednisone                | 104 (55.6)               | 73 (39.0)                | <0.001|
| Dose of Prednisone (mg)          | 5 (0 - 10)               | 0 (0 - 5)                | <0.001|

Mean and IQ for quantitative variables and n (%) for qualitative variables.

Table 4. Clinical characteristics and association with MS.

| Variables*                        | MS absent in both evaluations (n = 67) | MS present in the 1st evaluation and absent in the 2nd (n = 9) | MS absent in the 1st evaluation and present in the 2nd (n = 38) | MS present in both evaluations (n = 73) | P     |
|-----------------------------------|--------------------------------------|--------------------------------------------------------------|---------------------------------------------------------------|----------------------------------------|-------|
| Age at 1st evaluation (years)     | 51.5 ± 12.6a                         | 60.2 ± 8.6ab                                                 | 51.9 ± 9.6c                                                   | 56.5 ± 9.7b                           | 0.008 |
| Gender                            |                                       |                                                               |                                                               |                                        | 0.074 |
| Male                              | 16 (23.9)                            | 1 (11.1)                                                     | 2 (5.3)                                                       | 10 (13.7)                             |       |
| Female                            | 51 (76.1)                            | 8 (88.9)                                                     | 36 (94.7)                                                    | 63 (83.6)                             |       |
| BMI                               |                                       |                                                               |                                                               |                                        |       |
| 1st evaluation                    | 24.4 ± 4.2a                          | 27.3 ± 6.0ab                                                 | 26.1 ± 3.1a                                                   | 29.7 ± 5.3b                           | <0.001|
| 2nd evaluation                    | 25.4 ± 5.3a                          | 26.9 ± 6.1ab                                                 | 27.5 ± 3.8ab                                                  | 29.1 ± 5.2b                           | <0.001|
| Delta                             | 1.01 ± 2.56b                         | −0.41 ± 2.64ab                                               | 1.38 ± 3.31b                                                  | −0.59 ± 2.81b                         | 0.001 |
| DAS-28                            |                                       |                                                               |                                                               |                                        |       |
| 1st evaluation                    | 3.5 ± 1.5a                           | 3.6 ± 1.4ab                                                  | 4.3 ± 1.5b                                                    | 4.0 ± 1.3ab                           | 0.032 |
| 2nd evaluation                    | 3.3 ± 1.3                            | 4.5 ± 2.4                                                    | 3.7 ± 1.1                                                    | 3.5 ± 1.3                            | 0.052 |
| Delta                             | −0.2 ± 1.7                           | 0.9 ± 2.4                                                    | −0.6 ± 1.6                                                    | −0.5 ± 1.6                           | 0.076 |
| Moderate/high disease activity (>3.2) |                                   |                                                               |                                                               |                                        |       |
| 1st evaluation                    | 38 (56.7)                            | 6 (66.7)                                                     | 31 (81.6)                                                    | 51 (69.9)                             | 0.067 |
| 2nd evaluation                    | 32 (47.8)                            | 6 (66.7)                                                     | 25 (65.8)                                                    | 38 (52.1)                             | 0.276 |
| Dose of Prednisone                |                                       |                                                               |                                                               |                                        |       |
| 1st evaluation                    | 5 (0 - 10)ab                         | 0 (0 - 6.3)a                                                 | 10 (0 - 10)b                                                  | 0 (0 - 10)b                           | 0.031 |
| 2nd evaluation                    | 0 (0 - 5)                            | 0 (0 - 3.2)                                                  | 0 (0 - 5.6)                                                  | 0 (0 - 5)                            | 0.506 |
| Delta                             | 0.0 (−1.0 - 0.0)                     | 0 (0 - 0)                                                    | 0.0 (−1.0 - 0.0)                                             | 0.0 (0.0 - 0.0)                       | 0.539 |

The letters (a, b and ab) have the following meanings: a is different from b (significant difference); ab does not differ from either a or b.
the first evaluation (in spite of having developed or not MS at the second evaluation). It was also noted that patients who remained with MS in both evaluations were those with the highest BMI in both the first and second evaluations (29.7 ± 5.3 and 29.1 ± 5.2 mg/k², respectively, p > 0.05). There was a significant increase in BMI in those patients who did not have MS and developed it during the follow-up period (26.1 ± 3.1 and 27.5 ± 3.8, delta 1.38 ± 3.31, p < 0.05). In this group, DAS-28 was significantly higher, as well as the dose of prednisone.

Since the group that developed MS along the follow-up presented significant differences in the analyses of Table 4, a multivariate model was conducted in order to investigate possible risk factors for this specific condition, considering that the group that improved (no longer had MS) had a very small number of patients (n = 9). After adjustment by the multivariate model, significance remained for these following outcomes: variation of BMI (RR 1.12, 95% CI 1.02 - 1.23, p = 0.018), CRP (RR 1.01, 95% CI 1.00 - 1.02, P = 0.001), DAS-28 (RR 2.15, 95% CI 1.03 - 4.48, p = 0.041) and dose of prednisone in the 1st evaluation (RR 1.05, 95% CI 1.02 - 1.08, p = 0.001) (Table 5).

For patients who increased 1 kg/m² in BMI after eight years of follow-up, there was a 12% increase in the incidence of MS. Although CRP showed statistical significance, it did not remain significant when the 95% CI was considered. In addition, patients who had moderate/high disease activity in the 1st evaluation had 115% increased risk of developing MS, even though it has to be considered that the confidence interval was quite wide (95% CI 1.03 - 4.48, p = 0.041). Finally, with each increase of one unit in the dose of prednisone taken in the 1st evaluation, there was a 5% increase in the chance of developing MS.

When comparing the use of drugs with the improvement of the disease activity, only the use of biological drugs was significantly associated with improvement in DAS-28 scores from the 1st to the 2nd evaluation (p = 0.041). Improvement was

**Table 5.** Multivariate Poisson Regression analysis to evaluate independent factors associated with MS.

| Variables                                      | Relative Risk (RR) | 95% CI       | *P value |
|------------------------------------------------|--------------------|--------------|----------|
| Age at 1st evaluation (years)                  | 1.01               | 0.99 - 1.03  | 0.566    |
| Gender                                         |                    |              |          |
| Male                                           | 1.00               |              |          |
| Female                                         | 3.18               | 0.75 - 13.5  | 0.116    |
| BMI (Variation)                                | 1.12               | 1.02 - 1.23  | 0.018    |
| CRP 1st evaluation                             | 1.01               | 1.00 - 1.02  | 0.001    |
| DAS-28 (Moderate/high activity) 1st evaluation  | 2.15               | 1.03 - 4.48  | 0.041    |
| HAQ 1st evaluation                             | 0.71               | 0.46 - 1.08  | 0.110    |
| Use of Prednisone 1st evaluation               | 1.41               | 0.81 - 2.48  | 0.226    |
| Dose of Prednisone 1st evaluation              | 1.05               | 1.02 - 1.08  | 0.001    |

For the correction of confounding factors, a p value < 0.20 in the bivariate analysis met the criterion to enter the variable in the multivariate model.
found in 79.4% of those using biologicals versus 58.8% in patients who did not use. For the other medications, the differences were not significant (p > 0.05).

5. Discussion

RA and MS are considered diseases with shared characteristics that may increase the risk of cardiovascular diseases [13]. Researchers, therefore, focus their studies on the prevalence of MS in RA patients. We followed patients with RA and manifestations of MS for a period of 8 years, finding a 15% increase in the prevalence of MS, associated with parameters of disease activity, use of steroid and BMI.

Our results are consistent with previous studies with similar demographic profiles. Tantayakom et al. [14], between 2011 and 2015, also analyzed clinical and laboratory data of 267 patients with RA and MS according to the NCEP ATP III; 88% of the sample were women with mean age and standard deviation equal to 59 ± 11.1 years. In another study with 91 subjects with early AR and high rates of MS (35.2%), Muller et al. [14] found a correlation between age and gender, where the mean age was 52 years and 72.5% of the sample were women.

The correlation between RA and MS has been widely studied and the prevalence of MS in RA patients is higher when compared to the general population [13] [14] [15] [16] [17]. An Argentinian study [18] has evaluated the prevalence and correlation of MS with RA in 409 patients, and found a frequency of 30% according to the NCEP ATP III criteria and 35% according to the IDF criteria. Abourazzak et al. [19] investigated for a period of 17 months the prevalence of MS in Morocco in 179 patients with RA. The prevalence of MS in RA patients ranged from 24.6% to 30.7%, according to the definitions used (NCEP ATP III, IDF and American Association of Clinical Endocrinologists). A cross-sectional study conducted in the Northeastern Region of Brazil [20], with 110 patients with RA, showed a prevalence of MS of 50%, according to the NCEP ATP III criteria, and 53.4% according to the IDF. In a cohort with 384 Pakistani patients with RA [15], followed between July 2014 and June 2015, MS was found in 120 (31.3%), by the NCEP ATP III criteria. Our results, following the IDF criteria, determined that 31.55% patients had MS, in accordance with the international literature.

The study shows a wide range in the prevalence of MS in patients with RA. However, these values are consonant with the global prevalence that is estimated between 14% and 63%, justified by differences in epidemiology and methodology, such as the characteristics of the studied population, the origin of the patients, the criteria used to determine MS and the study design.

Since patients with RA have a higher prevalence of MS, management must be effective, reducing the possibility of cardiovascular diseases. In our study, we found a correlation between cholesterol and triglycerides levels and between systolic and diastolic blood pressures, which may further increase the risks of morbidity and mortality in these patients.
The correlations found and described in Table 2 are as expected, although they are weak or moderate correlations. This has most likely occurred because factors that were not evaluated may have influenced the results.

Disease activity is considered a factor that may increase the incidence of MS in patients with RA and is often mentioned in studies [21] [22] [23] [24] [25]. Among our patients, the disease activity at follow-up, based on DAS-28 [26], decreased from 3.88 ± 1.4 to 3.54 ± 1.35 and was statistically significant (p < 0.006), although it did not decrease to low activity or remission.

The main limitations of this study were the lack of a comparator group and the fact that the use of cardiovascular drugs was not evaluated.

After an 8-year follow-up, there was an increase of 15% in the number of cases with MS in this cohort of patients with established RA. Therefore, our study is consistent with the literature and shows the actual magnitude of MS in patients with established RA. It also represents the parameters in MS that vary in the population of RA patients, such as blood pressure, cholesterol and triglycerides. Consequently, it is imperative that we prevent the continuous inflammatory process and appropriately manage these parameters in order to have a better prognosis.

Acknowledgements

The authors thank FIPE-HCPA for its institutional support.

Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.

References

[1] Cojocaru, M., Cojocaru, I.M., Silosi, I. and Vrabie, C.D. (2012) Metabolic Syndrome in Rheumatoid Arthritis. Medica (Buchar), 7, 148-152.

[2] Dessein, P.H., Stanwix, A.E. and Joffe, B.I. (2002) Cardiovascular Risk in Rheumatoid Arthritis versus Osteoarthritis: Acute Phase Response Related Decreased Insulin Sensitivity and High-Density Lipoprotein Cholesterol as Well as Clustering of Metabolic Syndrome Features in Rheumatoid Arthritis. Arthritis Research, 4, R5. https://doi.org/10.1186/ar428

[3] Sattar, N., McCarey, D.W., Capell, H. and McInnes, I.B. (2003) Explaining How “High-Grade” Systemic Inflammation Accelerates Vascular Risk in Rheumatoid Arthritis. Circulation, 108, 2957-2963. https://doi.org/10.1161/01.CIR.0000099844.31524.05

[4] del Rincón, I., Freeman, G.L., Haas, R.W., et al. (2005) Relative Contribution of Cardiovascular Risk Factors and Rheumatoid Arthritis Clinical Manifestations to Atherosclerosis. Arthritis & Rheumatology, 52, 3413-3423. https://doi.org/10.1002/art.21397

[5] Hallajzadeh, J., Safiri, S. and Mansoumia, M.A., et al. (2017) Metabolic Syndrome and Its Components among Rheumatoid Arthritis Patients: A Comprehensive Updated Systematic Review and Meta-Analysis. PLoS ONE, 12, e0170361.
[6] Klæreskog, L., Wedrén, S. and Alfredsson, L. (2009) On the Origins of Complex Immune-Mediated Disease: The Example of Rheumatoid Arthritis. *Journal of Molecular Medicine (Berlin)*, 87, 357-362. https://doi.org/10.1007/s00109-008-0437-9

[7] da Cunha, V.R., Brenol, C.V., Brenol, J.C.T., *et al.* (2012) Metabolic Syndrome Prevalence Is Increased in Rheumatoid Arthritis Patients and Is Associated with Disease Activity. *Scandinavian Journal of Rheumatology*, 41, 186-191. https://doi.org/10.3109/03009742.2011.626443

[8] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA*, 285, 2486-2497. https://doi.org/10.1001/jama.285.19.2486

[9] WHO (1985) Physical Status: The Use and Interpretation of Anthropometry. Report of a WHO Expert Committee. World Health Organization Technical Report Series 854, 1-452.

[10] Sociedade Brasileira de Cardiologia (SBC) (2012) III Diretriz brasileira Sobre Dislipidemias e Prevenção da Aterosclerose do Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia. *Arquivos Brasileiros de Cardiologia*, 77, 2-19.

[11] Klimiuk, P.A., Yang, H., Goronzy, J.J. and Weyand, C.M. (1999) Production of Cytokines and Metalloproteinases in Rheumatoid Synovitis Is T Cell Dependent. *Clinical Immunology*, 90, 65-78. https://doi.org/10.1006/clim.1998.4618

[12] Harris, E.D. and Schur, P.H. (2009) Pathogenesis of Rheumatoid Arthritis. http://www.uptodate.com/contents/pathogenesis-of-rheumatoid-arthritis

[13] Aviña-Zubieta, J.A., Choi, H.K., Sadatsafavi, M., *et al.* (2008) Risk of Cardiovascular Mortality in Patients with Rheumatoid Arthritis: A Meta-Analysis of Observational Studies. *Arthritis & Rheumatology*, 59, 1690-1697. https://doi.org/10.1002/art.24092

[14] Tantayakom, P., Koolvisoot, A., Arromdee, E., *et al.* (2016) Metabolic Syndrome Is Associated with Disease Activity in Patients with Rheumatoid Arthritis. *Joint, Bone, Spine*, 83, 563-567. https://doi.org/10.1016/j.jbspin.2015.10.016

[15] Müller, R., Kull, M., Pölluste, K., *et al.* (2017) The Metabolic Profile in Early Rheumatoid Arthritis: A High Prevalence of Metabolic Obesity. *Rheumatology International*, 37, 21-27. https://doi.org/10.1007/s00296-016-3464-9

[16] Zafar, Z.A., Mahmud, T.H., Rasheed, A. and Wagan, A.A. (2016) Frequency of Metabolic Syndrome in Pakistani Cohort of Patients with Rheumatoid Arthritis. *Journal of Pakistan Medical Association*, 66, 671-676.

[17] Upchurch, K.S. and Kay, J. (2012) Evolution of Treatment for Rheumatoid Arthritis. *Rheumatology (Oxford)*, 51, vi28-vi36. https://doi.org/10.1093/rheumatology/kes278

[18] Salinas, M.J., Bertoli, A.M., Lema, L., *et al.* (2013) Prevalence and Correlates of Metabolic Syndrome in Patients with Rheumatoid Arthritis in Argentina. *Journal of Clinical Rheumatology*, 19, 439-443. https://doi.org/10.1097/RHU.0000000000000039

[19] Abourazzak, F.E., Mansouri, S., Najdi, A., *et al.* (2014) Prevalence of Metabolic Syndrome in Patients with Rheumatoid Arthritis in Morocco: A Cross-Sectional Study of 179 Cases. *Clinical Rheumatology*, 33, 1549-1555. https://doi.org/10.1007/s10067-014-2570-x

[20] de Oliveira, B.M.G.B., Medeiros, M.M. das C., de Cerqueira, J.V.M., *et al.* (2016) Metabolic Syndrome in Patients with Rheumatoid Arthritis Followed at a Universi-
ty Hospital in Northeastern Brazil. Revista Brasileira de Reumatologia, 56, 117-125. https://doi.org/10.1016/j.rbre.2015.08.016

[21] McInnes, I.B. and Schett, G. (2011) The Pathogenesis of Rheumatoid Arthritis. The New England Journal of Medicine, 365, 2205-2219. https://doi.org/10.1056/NEJMra1004965

[22] Lee, S.G., Kim, J.M., Lee, S.H., Kim, K.H., et al. (2013) Is the Frequency of Metabolic Syndrome Higher in South Korean Women with Rheumatoid Arthritis than in Healthy Subjects? The Korean Journal of Internal Medicine, 28, 206-215. https://doi.org/10.3904/kjim.2013.28.2.206

[23] Hernández-Hernández, V., Ferraz-Amaro, I. and Díaz-González, F. (2014) Influence of Disease Activity on the Physical Activity of Rheumatoid Arthritis Patients. Rheumatology (Oxford), 53, 722-731. https://doi.org/10.1093/rheumatology/ket422

[24] Bilecik, N.A., Tuna, S., Samancı, N., et al. (2014) Prevalence of Metabolic Syndrome in Women with Rheumatoid Arthritis and Effective Factors. International Journal of Clinical and Experimental Medicine, 7, 2258-2265.

[25] Bartlett, D.B., Connelly, M.A., AbouAssi, H., et al. (2016) A Novel Inflammatory Biomarker, GlycA, Associates with Disease Activity in Rheumatoid Arthritis and Cardio-Metabolic Risk in BMI-Matched Controls. Arthritis Research & Therapy, 18, 86. https://doi.org/10.1186/s13075-016-0982-5

[26] Wabe, N., Lee, A., Wechalekar, M., et al. (2017) Adherence to Combination DMARD Therapy and Treatment Outcomes in Rheumatoid Arthritis: A Longitudinal Study of New and Existing DMARD Users. Rheumatology International, 37, 897-904. https://doi.org/10.1007/s00296-017-3655-z
Research Protocol

Hospital de Clínicas de Porto Alegre-Department of Rheumatology
Prevalence and Incidence of Metabolic Syndrome in a Cohort of Patients
with Rheumatoid Arthritis: a correlation with Body Mass Index and Disease
Activity
Day/Month/Year: ____/____/____

CLINICAL EVALUATION
Patient’s name: ____________________ Medical record: _________________
Age: ____ years Birthday date: ____/____/_____ Sex: (       ) F (       ) M
Years of disease since diagnostic:_____________________________
Current medications: _________________________________________
________________________________________________________________
Previous diagnosis of CVD:
(    ) angina (    ) acute myocardial infarction (    ) stroke

BIOCHEMICAL EVALUATION:
Sample date: _____/____/____

| Evaluation          | Results |
|---------------------|---------|
| Total Cholesterol   |         |
| HDL                 |         |
| LDL                 |         |
| Triglycerides       |         |
| Fasting Glucose     |         |
| Fasting insulin     |         |
| Ultrasensitive CRP  |         |
| Free T4             |         |
| Ultrasensitive TSH  |         |

ANTHROPOMETRIC EVALUATION
Weight: ______ kg
Height: ________ cm
BMI: __________________ kg/m²
Waist Circumference: _____ cm

BLOOD PRESSURE MEASURES
BP: _____/_____ mmHg—1st verification
BP: _____/_____ mmHg—2nd verification
BP: _____/_____ mmHg – mean

METABOLIC SYNDROME DIAGNOSIS
| Condition                  | Criteria                                           |
|---------------------------|----------------------------------------------------|
| Waist Circumference       | >88 cm women                                       |
|                           | >102 cm men                                        |
| Triglycerides             | ≥150 mg/dL or on medication                        |
| HDL-c                     | <50 mg/dL women                                    |
|                           | <40 mg/dL men or on medication                     |
| Blood Pressure            | ≥130 and/or 85 mmHg                                |
|                           | Or on medication                                    |
| Fasting Glucose           | ≥100 mg/dL                                         |
|                           | Or on medication                                    |